Compare EVMN & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVMN | CGBD |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | 48 | 2500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.5M | 826.2M |
| IPO Year | N/A | N/A |
| Metric | EVMN | CGBD |
|---|---|---|
| Price | $22.84 | $11.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 8 |
| Target Price | ★ $43.88 | $12.92 |
| AVG Volume (30 Days) | 288.0K | ★ 685.7K |
| Earning Date | 06-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 14.42% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.74 |
| Revenue Next Year | N/A | $1.80 |
| P/E Ratio | ★ N/A | $10.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.89 | $10.64 |
| 52 Week High | $33.20 | $14.48 |
| Indicator | EVMN | CGBD |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 42.87 |
| Support Level | $21.39 | $11.19 |
| Resistance Level | $23.08 | $11.44 |
| Average True Range (ATR) | 1.56 | 0.30 |
| MACD | -0.20 | -0.08 |
| Stochastic Oscillator | 20.44 | 10.45 |
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.